Bone Morphogenetic Protein-2 Incorporated Beta-Tricalcium Phosphate Enhanced Bone Regeneration of Critical-Sized Bone Defects in Rats

Abstract:

Although preclinical and clinical studies have shown the benefits of bone morphogenetic protein-2 (BMP2) in bone regeneration, there are increasing concerns about its side effects. These are mainly due to the high dosage of BMP2 which is necessary to obtain the desired clinical results. Previously our group has developed a novel controlled-release delivery system; the biomimetic calcium phosphate coating incorporated with BMP2. It can be used at much lower concentrations of BMP2 than those used in the commercially available product and still produce similar biological effects. In this study, we made a primarily biological evaluation of BMP2 incorporated beta-tricalcium phosphate (β-TCP) for bone regeneration in critical-sized bone defects. Critical-sized calvarial defects were created in rats. They were divided into four groups as follows: (1) empty defects (control), (2) defects filled with β-TCP, (3) defects filled with BMP2 incorporated β-TCP, (4) defects filled with autologous bone. Eight weeks after the operation, the efficiency of the materials was evaluated using histology and histomorphometry. Moreover, the safety of the materials was evaluated using routine blood examination, blood biochemistry examination and histopathological examination of viscera. BMP2 incorporated β-TCP demonstrated an efficiency of bone regeneration that was comparable with autologous bone, with the highest levels of new bone formation (38.3±8.4 mm³ versus 30.1±9.9 mm³, p < 0.05). All clinical lab index of blood in these four groups were within the normal range. Moreover, no change related to the treatment was noted in the histopathological examination of viscera. The results from the present study demonstrated that BMP2 incorporated β-TCP could be a promising substitute for autologous bone used for bone regeneration. Future clinical trials and preclinical trials with large animal models are necessary to investigate the safety and efficacy of BMP2 incorporated β-TCP.

• Periodical: Key Engineering Materials (Volume 782)
• Pages: 283-288
• DOI: https://doi.org/10.4028/www.scientific.net/KEM.782.283
• Online since: October 2018
• Authors: Ling Fei Wei, Gang Wu, Li Quan Deng, Yue Lian Liu*
• Keywords: Biological Evaluation, Bone Morphogenetic Protein-2, Controlled-Release, Critical-Sized Bone Defects

References

[1] N.G. Janssen, W.L. Weijs, R. Koole, A.J. Rosenberg, G.J. Meijer, Tissue engineering strategies for alveolar cleft reconstruction: a systematic review of the literature, Clin Oral Investig 18(1) (2014) 219-26.

DOI: 10.1007/s00784-013-0947-x

[2] S. Samavedi, A.R. Whittington, A.S. Goldstein, Calcium phosphate ceramics in bone tissue engineering: a review of properties and their influence on cell behavior, Acta Biomater 9(9) (2013) 8037-45.

DOI: 10.1016/j.actbio.2013.06.014

[3] G. Rh Owen, M. Dard, H. Larjava, Hydoxyapatite/beta-tricalcium phosphate biphasic ceramics as regenerative material for the repair of complex bone defects, J Biomed Mater Res B Appl Biomater (2017).

DOI: 10.1002/jbm.b.34049

[4] J.M. Bouler, P. Pilet, O. Gauthier, E. Verron, Biphasic calcium phosphate ceramics for bone reconstruction: A review of biological response, Acta Biomater 53 (2017) 1-12.

DOI: 10.1016/j.actbio.2017.01.076

[5] M. Nilsson, M.H. Zheng, M. Tagil, The composite of hydroxyapatite and calcium sulphate: a review of preclinical evaluation and clinical applications, Expert Rev Med Devices 10(5) (2013) 675-84.

DOI: 10.1586/17434440.2013.827529

[6] A. El-Ghannam, Bone reconstruction: from bioceramics to tissue engineering, Expert Rev Med Devices 2(1) (2005) 87-101.

DOI: 10.1586/17434440.2.1.87

[7] M. Ronga, A. Fagetti, G. Canton, E. Paiusco, M.F. Surace, P. Cherubino, Clinical applications of growth factors in bone injuries: experience with BMPs, Injury 44 Suppl 1 (2013) S34-9.

DOI: 10.1016/s0020-1383(13)70008-1

[8] K.R. Garrison, I. Shemilt, S. Donell, J.J. Ryder, M. Mugford, I. Harvey, F. Song, V. Alt, Bone morphogenetic protein (BMP) for fracture healing in adults, Cochrane Database Syst Rev (6) (2010) CD006950.

DOI: 10.1002/14651858.cd006950.pub2

[9] A.C. Carreira, F.H. Lojudice, E. Halcsik, R.D. Navarro, M.C. Sogayar, J.M. Granjeiro, Bone morphogenetic proteins: facts, challenges, and future perspectives, J Dent Res 93(4) (2014) 335-45.

DOI: 10.1177/0022034513518561

[10] B. Poon, T. Kha, S. Tran, C.R. Dass, Bone morphogenetic protein-2 and bone therapy: successes and pitfalls, J Pharm Pharmacol 68(2) (2016) 139-47.

DOI: 10.1111/jphp.12506

[11] Y. Liu, E.B. Hunziker, P. Layrolle, J.D. De Bruijn, K. De Groot, Bone morphogenetic protein 2 incorporated into biomimetic coatings retains its biological activity, Tissue Eng 10(1-2) (2004) 101-8.

DOI: 10.1089/107632704322791745

[12] Y. Liu, K. de Groot, E.B. Hunziker, BMP-2 liberated from biomimetic implant coatings induces and sustains direct ossification in an ectopic rat model, Bone 36(5) (2005) 745-57.

DOI: 10.1016/j.bone.2005.02.005

[13] X. Lin, K. de Groot, D. Wang, Q. Hu, D. Wismeijer, Y. Liu, A review paper on biomimetic calcium phosphate coatings, Open Biomed Eng J 9 (2015) 56-64.

DOI: 10.2174/1874120701509010056

[14] T. Liu, G. Wu, Y. Zheng, D. Wismeijer, V. Everts, Y. Liu, Cell-mediated BMP-2 release from a novel dual-drug delivery system promotes bone formation, Clin Oral Implants Res 25(12) (2014) 1412-21.

DOI: 10.1111/clr.12283

[15] Y. Liu, C. Schouten, O. Boerman, G. Wu, J.A. Jansen, E.B. Hunziker, The kinetics and mechanism of BMP-2 release from calcium phosphate-based implant-coatings, J Biomed Mater Res A (2018).

DOI: 10.1002/jbm.a.36398

[16] Y. Zheng, G. Wu, T. Liu, Y. Liu, D. Wismeijer, Y. Liu, A novel BMP2-coprecipitated, layer-by-layer assembled biomimetic calcium phosphate particle: a biodegradable and highly efficient osteoinducer, Clin Implant Dent Relat Res 16(5) (2014).

DOI: 10.1111/cid.12050

[17] D. Wang, A. Tabassum, G. Wu, L. Deng, D. Wismeijer, Y. Liu, Bone regeneration in critical-sized bone defect enhanced by introducing osteoinductivity to biphasic calcium phosphate granules, Clin Oral Implants Res 28(3) (2017) 251-260.

DOI: 10.1111/clr.12791